Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology

Open Access 08-05-2024 | Gastric Cancer | Review

Research advances in the molecular classification of gastric cancer

Authors: Dike Shi, Zihan Yang, Yanna Cai, Hongbo Li, Lele Lin, Dan Wu, Shengyu Zhang, Qingqu Guo

Published in: Cellular Oncology

Login to get access

Abstract

Gastric cancer (GC) is a malignant tumor with one of the lowest five-year survival rates. Traditional first-line treatment regimens, such as platinum drugs, have limited therapeutic efficacy in treating advanced GC and significant side effects, greatly reducing patient quality of life. In contrast, trastuzumab and other immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have demonstrated consistent and reliable efficacy in treating GC. Here, we discuss the intrinsic characteristics of GC from a molecular perspective and provide a comprehensive review of classification and treatment advances in the disease. Finally, we suggest several strategies based on the intrinsic molecular characteristics of GC to aid in overcoming clinical challenges in the development of precision medicine and improve patient prognosis.
Literature
1.
H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 71(3), 209–249 (2021)CrossRef
2.
M. Rugge, Gastric cancer risk: between genetics and lifestyle. Lancet Oncol. 21(10), 1258–1260 (2020)PubMedCrossRef
3.
E.C. Smyth, M. Nilsson, H.I. Grabsch, N.C. van Grieken, F. Lordick, Gastric cancer. Lancet 396(10251), 635–648 (2020)PubMedCrossRef
4.
J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Estimates of worldwide burden of cancer in 2008: globocan 2008. Int. J. Cancer 127(12), 2893–2917 (2010)PubMedCrossRef
5.
M. Venerito, A. Link, T. Rokkas, P. Malfertheiner, Gastric cancer - clinical and epidemiological aspects. Helicobacter 21(Suppl 1), 39–44 (2016)PubMedCrossRef
6.
M.J. Lopez, J. Carbajal, A.L. Alfaro, L.G. Saravia, D. Zanabria, J.M. Araujo, L. Quispe, A. Zevallos, J.L. Buleje, C.E. Cho, M. Sarmiento, J.A. Pinto, W. Fajardo, Characteristics of gastric cancer around the world. Crit. Rev. Oncol. Hematol. 181, 103841 (2023)PubMedCrossRef
7.
V. Pasechnikov, S. Chukov, E. Fedorov, I. Kikuste, M. Leja, Gastric cancer: prevention, screening and early diagnosis. World J. Gastroenterol. 20(38), 13842–13862 (2014)PubMedPubMedCentralCrossRef
8.
M. Ito, S. Tanaka, K. Chayama, Characteristics and early diagnosis of gastric cancer discovered after helicobacter pylori eradication. Gut. Liver 15(3), 338–345 (2021)PubMedCrossRef
9.
L. Necula, L. Matei, D. Dragu, A.I. Neagu, C. Mambet, S. Nedeianu, C. Bleotu, C.C. Diaconu, M. Chivu-Economescu, Recent advances in gastric cancer early diagnosis. World J. Gastroenterol. 25(17), 2029–2044 (2019)PubMedPubMedCentralCrossRef
10.
P. Karimi, F. Islami, S. Anandasabapathy, N.D. Freedman, F. Kamangar, Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol. Biomarkers Prev. 23(5), 700–713 (2014)PubMedPubMedCentralCrossRef
11.
J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, R. Sitarz, Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int. J. Mol. Sci. 21(11) (2020)
12.
M. Cavaleiro-Pinto, B. Peleteiro, N. Lunet, H. Barros, Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control. 22(3), 375–387 (2011)PubMedCrossRef
13.
E. Yakirevich, M.B. Resnick, Pathology of gastric cancer and its precursor lesions. Gastroenterol. Clin. North Am. 42(2), 261–284 (2013)PubMedCrossRef
14.
L. Yang, C. Kartsonaki, P. Yao, C. de Martel, M. Plummer, D. Chapman, Y. Guo, S. Clark, R.G. Walters, Y. Chen, P. Pei, J. Lv, C. Yu, R. Jeske, T. Waterboer, G.M. Clifford, S. Franceschi, R. Peto, M. Hill, L. Li, I.Y. Millwood, Z. Chen, G. China Kadoorie Biobank Collaborative, The relative and attributable risks of cardia and non-cardia gastric cancer associated with helicobacter pylori infection in china: a case-cohort study. Lancet Public Health 6(12), 888–896 (2021)CrossRef
15.
P. Lauren, The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31–49 (1965)PubMedCrossRef
16.
B. Hu, N. El Hajj, S. Sittler, N. Lammert, R. Barnes, A. Meloni-Ehrig, Gastric cancer: classification, histology and application of molecular pathology. J. Gastrointest. Oncol. 3(3), 251–261 (2012)PubMedPubMedCentral
17.
K.M. Kim, M.S. Kwon, S.J. Hong, K.O. Min, E.J. Seo, K.Y. Lee, S.W. Choi, M.G.J.V.A. Rhyu, Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability. Virchows Arch. 443(4), 491–500 (2003)PubMedCrossRef
18.
S.T. Tay, S.H. Leong, K. Yu, A. Aggarwal, S.Y. Tan, C.H. Lee, K. Wong, J. Visvanathan, D. Lim, W.K. Wong, K.C. Soo, O.L. Kon, P. Tan, A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res. 63(12), 3309–3316 (2003)PubMed
19.
I.B. Tan, T. Ivanova, K.H. Lim, C.W. Ong, N. Deng, J. Lee, S.H. Tan, J. Wu, M.H. Lee, C.H. Ooi, S.Y. Rha, W.K. Wong, A. Boussioutas, K.G. Yeoh, J. So, W.P. Yong, A. Tsuburaya, H. Grabsch, H.C. Toh, S. Rozen, J.H. Cheong, S.H. Noh, W.K. Wan, J.A. Ajani, J.S. Lee, M.S. Tellez, P. Tan, Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141(2), 476–85485111 (2011)PubMedCrossRef
20.
Z. Lei, I.B. Tan, K. Das, N. Deng, H. Zouridis, S. Pattison, C. Chua, Z. Feng, Y.K. Guan, C.H. Ooi, T. Ivanova, S. Zhang, M. Lee, J. Wu, A. Ngo, S. Manesh, E. Tan, B.T. Teh, J.B. So, L.K. Goh, A. Boussioutas, T.K. Lim, H. Flotow, P. Tan, S.G. Rozen, Identification of molecular subtypes of gastric cancer with different responses to pi3-kinase inhibitors and 5-fluorouracil. Gastroenterology 145(3), 554–565 (2013)PubMedCrossRef
21.
N. Cancer Genome Atlas Research, Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202–209 (2014)CrossRef
22.
R. Cristescu, J. Lee, M. Nebozhyn, K.M. Kim, J.C. Ting, S.S. Wong, J. Liu, Y.G. Yue, J. Wang, K. Yu, X.S. Ye, I.G. Do, S. Liu, L. Gong, J. Fu, J.G. Jin, M.G. Choi, T.S. Sohn, J.H. Lee, J.M. Bae, S.T. Kim, S.H. Park, I. Sohn, S.H. Jung, P. Tan, R. Chen, J. Hardwick, W.K. Kang, M. Ayers, D. Hongyue, C. Reinhard, A. Loboda, S. Kim, A. Aggarwal, Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21(5), 449–456 (2015)PubMedCrossRef
23.
E.O. Ignatova, E. Kozlov, M. Ivanov, V. Mileyko, S. Menshikova, H. Sun, M. Fedyanin, A. Tryakin, I. Stilidi, Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma. World J. Gastrointest Oncol. 14(3), 628–645 (2022)PubMedPubMedCentralCrossRef
24.
25.
26.
M. Alsina, V. Arrazubi, M. Diez, J. Tabernero, Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat. Rev. Gastroenterol. Hepatol. 20(3), 155–170 (2023)PubMedCrossRef
27.
A. Shinozaki-Ushiku, A. Kunita, M. Fukayama, Update on epstein-barr virus and gastric cancer (review). Int. J. Oncol. 46(4), 1421–1434 (2015)PubMedCrossRef
28.
Y. Du, J.Y. Zhang, L.P. Gong, Z.Y. Feng, D. Wang, Y.H. Pan, L.P. Sun, J.Y. Wen, G.F. Chen, J. Liang, J.N. Chen, C.K. Shao, Hypoxia-induced ebv- circlmp2a promotes angiogenesis in ebv-associated gastric carcinoma through the khsrp/vhl/hif1alpha/vegfa pathway. Cancer Lett. 526, 259–272 (2022)PubMedCrossRef
29.
J. Ribeiro, A. Oliveira, M. Malta, C. Oliveira, F. Silva, A. Galaghar, L.P. Afonso, M.C. Neves, R. Medeiros, P. Pimentel-Nunes, H. Sousa, Clinical and pathological characterization of epstein-barr virus-associated gastric carcinomas in portugal. World J. Gastroenterol. 23(40), 7292–7302 (2017)PubMedPubMedCentralCrossRef
30.
M. Naseem, A. Barzi, C. Brezden-Masley, A. Puccini, M.D. Berger, R. Tokunaga, F. Battaglin, S. Soni, M. McSkane, W. Zhang, H.J. Lenz, Outlooks on epstein-barr virus associated gastric cancer. Cancer Treat Rev. 66, 15–22 (2018)PubMedPubMedCentralCrossRef
31.
M.S. Chang, H. Uozaki, J.M. Chong, T. Ushiku, K. Sakuma, S. Ishikawa, R. Hino, R.R. Barua, Y. Iwasaki, K. Arai, H. Fujii, H. Nagai, M. Fukayama, Cpg island methylation status in gastric carcinoma with and without infection of epstein-barr virus. Clin. Cancer. Res. 12(10), 2995–3002 (2006)PubMedCrossRef
32.
F. Lu, I. Tempera, H.T. Lee, K. Dewispelaere, P.M. Lieberman, Ebna1 binding and epigenetic regulation of gastrokine tumor suppressor genes in gastric carcinoma cells. Virol. J. 11, 12 (2014)PubMedPubMedCentralCrossRef
33.
J. Zhao, Q. Liang, K.F. Cheung, W. Kang, R.W. Lung, J.H. Tong, K.F. To, J.J. Sung, J. Yu, Genome-wide identification of epstein-barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer 119(2), 304–312 (2013)PubMedCrossRef
34.
M.S. Chang, D.H. Kim, J.K. Roh, J.M. Middeldorp, Y.S. Kim, S. Kim, S. Han, C.W. Kim, B.L. Lee, W.H. Kim, J.H. Woo, Epstein-barr virus-encoded barf1 promotes proliferation of gastric carcinoma cells through regulation of nf-kappab. J. Virol. 87(19), 10515–10523 (2013)PubMedPubMedCentralCrossRef
35.
X. Zheng, J. Wang, L. Wei, Q. Peng, Y. Gao, Y. Fu, Y. Lu, Z. Qin, X. Zhang, J. Lu, C. Ou, Z. Li, X. Zhang, P. Liu, W. Xiong, G. Li, Q. Yan, J. Ma, Epstein-barr virus microrna mir-bart5-3p inhibits p53 expression. J. Virol. 92(23) (2018)
36.
R. Hino, H. Uozaki, Y. Inoue, Y. Shintani, T. Ushiku, T. Sakatani, K. Takada, M. Fukayama, Survival advantage of ebv-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2a. Cancer Res. 68(5), 1427–1435 (2008)PubMedCrossRef
37.
A. Shinozaki-Ushiku, A. Kunita, M. Isogai, T. Hibiya, T. Ushiku, K. Takada, M. Fukayama, Profiling of virus-encoded micrornas in epstein-barr virus- associated gastric carcinoma and their roles in gastric carcinogenesis. J. Virol. 89(10), 5581–5591 (2015)PubMedPubMedCentralCrossRef
38.
Q. Wang, S.W. Tsao, T. Ooka, J.M. Nicholls, H.W. Cheung, S. Fu, Y.C. Wong, X. Wang, Anti-apoptotic role of barf1 in gastric cancer cells. Cancer Lett. 238(1), 90–103 (2006)PubMedCrossRef
39.
T.C. Cheng, S.S. Hsieh, W.L. Hsu, Y.F. Chen, H.H. Ho, L.F. Sheu, Expression of epstein-barr nuclear antigen 1 in gastric carcinoma cells is associated with enhanced tumorigenicity and reduced cisplatin sensitivity. Int. J. Oncol. 36(1), 151–160 (2010)PubMed
40.
M.L. Gulley, Genomic assays for epstein-barr virus-positive gastric adenocarci- noma. Exp. Mol. Med. 47(1), 134 (2015)CrossRef
41.
M. Dong, H.Y. Wang, X.X. Zhao, J.N. Chen, Y.W. Zhang, Y. Huang, L. Xue, H.G. Li, H. Du, X.Y. Wu, C.K. Shao, Expression and prognostic roles of pik3ca, jak2, pd-l1, and pd-l2 in epstein-barr virus-associated gastric carcinoma. Hum. Pathol. 53, 25–34 (2016)PubMedCrossRef
42.
N. Han, M.A. Kim, H.S. Lee, W.H. Kim, Loss of arid1a expression is related to gastric cancer progression, epstein-barr virus infection, and mismatch repair deficiency. Appl. Immunohistochem. Mol. Morphol. 24(5), 320–325 (2016)PubMedCrossRef
43.
A. Dobashi, N. Tsuyama, R. Asaka, Y. Togashi, K. Ueda, S. Sakata, S. Baba, K. Sakamoto, K. Hatake, K. Takeuchi, Frequent bcor aberrations in extranodal nk/t-cell lymphoma, nasal type. Genes Chromosomes Cancer 55(5), 460–471 (2016)PubMedCrossRef
44.
T. Shuto, J. Nishikawa, K. Shimokuri, A. Yanagi, T. Takagi, F. Takagi, O. Miura, M. Iida, H. Nagano, Y. Takemoto, E. Harada, Y. Suehiro, T. Yamasaki, T. Okamoto, I. Sakaida, Establishment of a screening method for epstein-barr virus-associated gastric carcinoma by droplet digital pcr. Microorganisms 7(12) (2019)
45.
M. Fukayama, J.M. Chong, Y. Kaizaki, S. Sakurai, State of art: epstein barr virus-associated gastric carcinoma. Nihon Rinsho. 55(2), 357–362 (1997)PubMed
46.
J.N. Chen, D. He, F. Tang, C.K. Shao, Epstein-barr virus-associated gastric carcinoma: a newly defined entity. J. Clin. Gastroenterol. 46(4), 262–271 (2012)PubMedCrossRef
47.
S. Akiba, C. Koriyama, R. Herrera-Goepfert, Y. Eizuru, Epstein-barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci. 99(2), 195–201 (2008)PubMedCrossRef
48.
49.
S.Z. Deng, X.X. Wang, X.Y. Zhao, Y.M. Bai, H.M. Zhang, Exploration of the tumor immune landscape and identification of two novel immunotherapy- related genes for epstein-barr virus-associated gastric carcinoma via integrated bioinformatics analysis. Front. Surg. 9, 898733 (2022)PubMedPubMedCentralCrossRef
50.
K. Mimura, L.F. Kua, J.F. Xiao, B.R. Asuncion, Y. Nakayama, N. Syn, Z. Fazreen, R. Soong, K. Kono, W.P. Yong, Combined inhibition of pd-1/pd- l1, lag-3, and tim-3 axes augments antitumor immunity in gastric cancer-t cell coculture models. Gastric Cancer 24(3), 611–623 (2021)PubMedPubMedCentralCrossRef
51.
M.Z. Qiu, C.Y. He, S.X. Lu, W.L. Guan, F. Wang, X.J. Wang, Y. Jin, F.H. Wang, Y.H. Li, J.Y. Shao, Z.W. Zhou, J.P. Yun, R.H. Xu, Prospective observation: clinical utility of plasma epstein-barr virus dna load in ebv-associated gastric carcinoma patients. Int. J. Cancer 146(1), 272–280 (2020)PubMedCrossRef
52.
E.P. Hui, W.F. Li, B.B. Ma, W.K.J. Lam, K.C.A. Chan, F. Mo, Q.Y.H. Ai, A.D. King, C.H. Wong, R. Guo, D.M.C. Poon, M. Tong, L. Li, T.K.H. Lau, K.C.W. Wong, D.C.M. Lam, Y.M.D. Lo, J. Ma, A.T.C. Chan, Integrating postradiotherapy plasma epstein-barr virus dna and tnm stage for risk strat- ification of nasopharyngeal carcinoma to adjuvant therapy. Ann. Oncol. 31(6), 769–779 (2020)PubMedCrossRef
53.
H. Yamamoto, K. Imai, Microsatellite instability: an update. Arch. Toxicol. 89(6), 899–921 (2015)PubMedCrossRef
54.
R.J. Hause, C.C. Pritchard, J. Shendure, S.J. Salipante, Corrigendum: classi- fication and characterization of microsatellite instability across 18 cancer types. Nat. Med. 24(4), 525 (2018)PubMedCrossRef
55.
M.L. DuPrie, T. Palacio, F.A. Calil, R.D. Kolodner, C.D. Putnam, Mlh1 interacts with both msh2 and msh6 for recruitment during mismatch repair. DNA Repair (Amst) 119, 103405 (2022)PubMedCrossRef
56.
S.N. Thibodeau, G. Bren, D. Schaid, Microsatellite instability in cancer of the proximal colon. Science 260(5109), 816–819 (1993)PubMedCrossRef
57.
J.G. Strickler, J. Zheng, Q. Shu, L.J. Burgart, S.R. Alberts, D. Shibata, P53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res. 54(17), 4750–4755 (1994)PubMed
58.
M.G. Rhyu, W.S. Park, S.J. Meltzer, Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene 9(1), 29–32 (1994)PubMed
59.
A. Merlo, M. Mabry, E. Gabrielson, R. Vollmer, S.B. Baylin, D. Sidransky, Frequent microsatellite instability in primary small cell lung cancer. Cancer Res. 54(8), 2098–2101 (1994)PubMed
60.
B.D. Duggan, J.C. Felix, L.I. Muderspach, D. Tourgeman, J. Zheng, D. Shibata, Microsatellite instability in sporadic endometrial carcinoma. J. Natl. Cancer Inst. 86(16), 1216–1221 (1994)PubMedCrossRef
61.
G.L. De’ Angelis, L. Bottarelli, C. Azzoni, N. De’ Angelis, G. Leandro, F. Di Mario, F. Gaiani, F. Negri, Microsatellite instability in colorectal cancer. Acta Biomed. 89(9-S), 97–101 (2018)PubMed
62.
R. Sugimoto, M. Endo, M. Osakabe, Y. Toya, N. Yanagawa, T. Matsumoto, T. Sugai, Immunohistochemical analysis of mismatch repair gene proteins in early gastric cancer based on microsatellite status. Digestion 102(5), 691–700 (2021)PubMedCrossRef
63.
E. Puliga, S. Corso, F. Pietrantonio, S. Giordano, Microsatellite instability in gastric cancer: between lights and shadows. Cancer Treat Rev. 95, 102175 (2021)PubMedCrossRef
64.
C. Guastadisegni, M. Colafranceschi, L. Ottini, E. Dogliotti, Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur. J. Cancer 46(15), 2788–2798 (2010)PubMedCrossRef
65.
F. Pietrantonio, G. Randon, M. Di Bartolomeo, A. Luciani, J. Chao, E.C. Smyth, F. Petrelli, Predictive role of microsatellite instability for pd-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open 6(1), 100036 (2021)PubMedPubMedCentralCrossRef
66.
H. Jin, P. Li, C. Mao, K. Zhu, H. Chen, Y. Gao, J. Yu, Pathological complete response after a single dose of anti-pd-1 therapy in combination with chemotherapy as a first-line setting in an unresectable locally advanced gastric cancer with pd-l1 positive and microsatellite instability. Onco. Targets Ther. 13, 1751–1756 (2020)PubMedPubMedCentralCrossRef
67.
68.
69.
Y.F. Gao, T. Li, Y. Chang, Y.B. Wang, W.N. Zhang, W.H. Li, K. He, R. Mu, C. Zhen, J.H. Man, X. Pan, T. Li, L. Chen, M. Yu, B. Liang, Y. Chen, Q. Xia, T. Zhou, W.L. Gong, A.L. Li, H.Y. Li, X.M. Zhang, Cdk1-phosphorylated cuedc2 promotes spindle checkpoint inactivation and chromosomal instability. Nat. Cell Biol. 13(8), 924–933 (2011)PubMedCrossRef
70.
A. Stolz, N. Ertych, H. Bastians, Tumor suppressor chk2: regulator of dna damage response and mediator of chromosomal stability. Clin. Cancer. Res. 17(3), 401–405 (2011)PubMedCrossRef
71.
H.J. Nam, S. Chae, S.H. Jang, H. Cho, J.H. Lee, The pi3k-akt mediates oncogenic met-induced centrosome amplification and chromosome instability. Carcinogenesis 31(9), 1531–1540 (2010)PubMedCrossRef
72.
C.E. Bond, A. Umapathy, R.L. Buttenshaw, L. Wockner, B.A. Leggett, V.L. Whitehall, Chromosomal instability in braf mutant, microsatellite stable colorectal cancers. PLoS ONE 7(10), 47483 (2012)CrossRef
73.
S.Y. Lee, C. Jang, K.A. Lee, Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy. Dev. Reprod. 18(1), 65–71 (2014)PubMedPubMedCentralCrossRef
74.
S.E. McClelland, Role of chromosomal instability in cancer progression. Endocr. Relat. Cancer 24(9), 23–31 (2017)CrossRef
75.
E. Albers, M. Sbroggio, D. Pladevall-Morera, A.H. Bizard, A. Avram, P. Gonzalez, J. Martin-Gonzalez, I.D. Hickson, A.J. Lopez-Contreras, Loss of pich results in chromosomal instability, p53 activation, and embryonic lethality. Cell Rep. 24(12), 3274–3284 (2018)PubMedPubMedCentralCrossRef
76.
Y. Hisamatsu, E. Oki, H. Otsu, K. Ando, H. Saeki, E. Tokunaga, S. Aishima, M. Morita, Y. Oda, Y. Maehara, Effect of egfr and p-akt overexpression on chromosomal instability in gastric cancer. Ann. Surg. Oncol. 23(6), 1986–1992 (2016)PubMedCrossRef
77.
T. Poghosyan, S. Krivan, C. Baratte, Bile or acid reflux post one-anastomosis gastric bypass: what must we do? still an unsolved enigma. J. Clin. Med. 11(12) (2022)
78.
M.R. Ippolito, V. Martis, S. Martin, A.E. Tijhuis, C. Hong, R. Wardenaar, M. Dumont, J. Zerbib, D.C.J. Spierings, D. Fachinetti, U. Ben-David, F. Foijer, S. Santaguida, Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. Dev. Cell 56(17), 2440–24546 (2021)PubMedCrossRef
79.
P. Jimenez Fonseca, A. Carmona-Bayonas, R. Hernandez, A. Custodio, J.M. Cano, A. Lacalle, I. Echavarria, I. Macias, M. Mangas, L. Visa, E. Buxo, F. Alvarez Mancenido, A. Viudez, C. Pericay, A. Azkarate, A. Ramchandani, C. Lopez, E. Martinez de Castro, A. Fernandez Montes, F. Longo, R. Sanchez Bayona, M.L. Limon, A. Diaz-Serrano, A. Martin Carnicero, D. Arias, P. Cerda, F. Rivera, J.M. Vieitez, M. Sanchez Canovas, M. Garrido, J. Gallego, Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the agamenon national cancer registry. Br. J. Cancer 117(6), 775–782 (2017)PubMedPubMedCentralCrossRef
80.
G. Usui, K. Matsusaka, Y. Mano, M. Urabe, S. Funata, M. Fukayama, T. Ushiku, A. Kaneda, Dna methylation and genetic aberrations in gastric cancer. Digestion 102(1), 25–32 (2021)PubMedCrossRef
81.
W.H. Zhang, S.Y. Zhang, Q.Q. Hou, Y. Qin, X.Z. Chen, Z.G. Zhou, Y. Shu, H. Xu, J.K. Hu, The significance of the cldn18-arhgap fusion gene in gastric cancer: a systematic review and meta-analysis. Front. Oncol. 10, 1214 (2020)PubMedPubMedCentralCrossRef
82.
J. Chu, X.C. Hu, C.C. Li, T.Y. Li, H.W. Fan, G.Q. Jiang, Klf14 alleviated breast cancer invasion and m2 macrophages polarization through modulating socs3/rhoa/rock/stat3 signaling. Cell Signal 92, 110242 (2022)PubMedCrossRef
83.
H. Liu, Y. Liu, X. Zhang, X. Wang, Current study of rhoa and associated signaling pathways in gastric cancer. Curr. Stem. Cell Res. Ther. 15(7), 607–613 (2020)PubMedCrossRef
84.
G.Y. Zhang, W.H. Yang, Z. Chen, Upregulated stat3 and rhoa signaling in colorectal cancer (crc) regulate the invasion and migration of crc cells. Eur. Rev. Med. Pharmacol. Sci. 20(10), 2028–2037 (2016)PubMed
85.
86.
H. Zhang, A. Schaefer, Y. Wang, R.G. Hodge, D.R. Blake, J.N. Diehl, A.G. Papageorge, M.D. Stachler, J. Liao, J. Zhou, Z. Wu, F.G. Akarca, L.K. de Klerk, S. Derks, M. Pierobon, K.A. Hoadley, T.C. Wang, G. Church, K.K. Wong, E.F. Petricoin, A.D. Cox, D.R. Lowy, C.J. Der, A.J. Bass, Gain-of-function rhoa mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer. Cancer Discov. 10(2), 288–305 (2020)PubMedCrossRef
87.
88.
89.
F. Yao, J.P. Kausalya, Y.Y. Sia, A.S. Teo, W.H. Lee, A.G. Ong, Z. Zhang, J.H. Tan, G. Li, D. Bertrand, X. Liu, H.M. Poh, P. Guan, F. Zhu, T.N. Pathiraja, P.N. Ariyaratne, J. Rao, X.Y. Woo, S. Cai, F.H. Mulawadi, W.T. Poh, L. Veeravalli, C.S. Chan, S.S. Lim, S.T. Leong, S.C. Neo, P.S. Choi, E.G. Chew, N. Nagarajan, P.E. Jacques, J.B. So, X. Ruan, K.G. Yeoh, P. Tan, W.K. Sung, W. Hunziker, Y. Ruan, A.M. Hillmer, Recurrent fusion genes in gastric cancer: cldn18-arhgap26 induces loss of epithelial integrity. Cell Rep. 12(2), 272–285 (2015)PubMedCrossRef
90.
S. Wang, C. Qi, J. Ding, D. Li, M. Zhang, C. Ji, F. Jiang, F. Teng, J. Yu, X. Qian, F. Wang, L. Shen, J. Gao, Z. Yang, C. Zhang, H. Zhu, First-in- human cldn18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. Eur. J. Nucl. Med. Mol. Imaging (2023)
91.
Y. Yamakoshi, H. Tanaka, C. Sakimura, S. Deguchi, T. Mori, T. Tamura, T. Toyokawa, K. Muguruma, K. Hirakawa, M. Ohira, Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer. Int. J. Oncol. 57(1), 171–182 (2020)PubMedPubMedCentral
92.
H. Konno, T. Lin, R. Wu, X. Dai, S. Li, G. Wang, M. Chen, W. Li, L. Wang, B.C. Sun, Z. Luo, T. Huang, Y. Chen, J. Zhang, Q. Ye, D. Bellovin, B. Wan, L. Kang, C. Szeto, K. Hsu, O. Kabbarah, Zl-1211 exhibits robust antitumor activity by enhancing adcc and activating nk cell-mediated inflammation in cldn18.2-high and -low expressing gastric cancer models. Cancer Res. Commun. 2(9), 937–950 (2022)PubMedPubMedCentralCrossRef
93.
B.H. Sohn, J.E. Hwang, H.J. Jang, H.S. Lee, S.C. Oh, J.J. Shim, K.W. Lee, E.H. Kim, S.Y. Yim, S.H. Lee, J.H. Cheong, W. Jeong, J.Y. Cho, J. Kim, J. Chae, J. Lee, W.K. Kang, S. Kim, S.H. Noh, J.A. Ajani, J.S. Lee, Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin. Cancer. Res. 23(15), 4441–4449 (2017)PubMedPubMedCentralCrossRef
94.
A. Korourian, R. Roudi, A. Shariftabrizi, Z. Madjd, Microrna-31 inhibits rhoa-mediated tumor invasion and chemotherapy resistance in mkn-45 gastric adenocarcinoma cells. Exp. Biol. Med. (Maywood) 242(18), 1842–1847 (2017)PubMedCrossRef
95.
C. Yoon, S.J. Cho, B.A. Aksoy, D.J. Park, N. Schultz, S.W. Ryeom, S.S. Yoon, Chemotherapy resistance in diffuse-type gastric adenocarcinoma is mediated by rhoa activation in cancer stem-like cells. Clin. Cancer. Res. 22(4), 971–983 (2016)PubMedCrossRef
96.
E. Pretzsch, F. Bosch, R. Todorova, H. Niess, S. Jacob, M. Guba, T. Kirchner, J. Werner, F. Klauschen, M.K. Angele, J. Neumann, Molecular subtyping of gastric cancer according to acrg using immunohistochemistry - correlation with clinical parameters. Pathol. Res. Pract. 231, 153797 (2022)PubMedCrossRef
97.
H. Zhang, S. Zhen, P. Ding, B. Tan, H. Wang, W. Liu, Y. Tian, Q. Zhao, Screening of differentially expressed genes based on the acrg molecular subtypes of gastric cancer and the significance and mechanism of agtr1 gene expression. J. Pers. Med. 13(3) (2023)
98.
J.P. Nshizirungu, S. Bennis, I. Mellouki, M. Sekal, D.A. Benajah, N. Lahmi-dani, H. El Bouhaddouti, K. Ibn Majdoub, S.A. Ibrahimi, S.P. Celeiro, M. Viana-Pereira, F.F. Munari, G.G. Ribeiro, V. Duval, I. Santana, R.M. Reis, Reproduction of the cancer genome atlas (tcga) and asian cancer research group (acrg) gastric cancer molecular classifications and their association with clinicopathological characteristics and overall survival in moroccan patients. Dis. Markers 2021, 9980410 (2021)PubMedPubMedCentralCrossRef
99.
V. Angerilli, G. Pennelli, F. Galuppini, S. Realdon, A. Fantin, E. Savarino, F. Farinati, L. Mastracci, C. Luchini, M. Fassan, Molecular subtyping of gastroesophageal dysplasia heterogeneity according to tcga/acrg classes. Virchows Arch. 481(4), 545–552 (2022)PubMedPubMedCentralCrossRef
100.
Q. Wang, Q. Xie, Y. Liu, H. Guo, Y. Ren, J. Li, Q. Zhao, Clinical character- istics and prognostic significance of tcga and acrg classification in gastric cancer among the chinese population. Mol. Med. Rep. 22(2), 828–840 (2020)PubMedPubMedCentralCrossRef
101.
102.
J. Xiao, L. Zheng, J. Liu, Comprehensive analysis of the aberrance and func- tional significance of ferroptosis in gastric cancer. Front. Pharmacol. 13, 919490 (2022)PubMedPubMedCentralCrossRef
103.
Y. Lin, K. Huang, Z. Cai, Y. Chen, L. Feng, Y. Gao, W. Zheng, X. Fan, G. Qiu, J. Zhuang, S. Feng, A novel exosome-relevant molecular classification uncovers distinct immune escape mechanisms and genomic alterations in gastric cancer. Front. Pharmacol. 13, 884090 (2022)PubMedPubMedCentralCrossRef
104.
Y. Dong, Q. Yuan, J. Ren, H. Li, H. Guo, H. Guan, X. Jiang, B. Qi, R. Li, Identification and characterization of a novel molecular classification incorporating oxidative stress and metabolism-related genes for stomach adenocarcinoma in the framework of predictive, preventive, and personalized medicine. Front. Endocrinol. (Lausanne) 14, 1090906 (2023)PubMedCrossRef
105.
W.-L. Guan, Y. He, R.-H. Xu, Gastric cancer treatment: recent progress and future perspectives. J. Hematol. Oncol. 16, 57 (2023)
106.
Y. Li, C. Xu, B. Wang, F. Xu, F. Ma, Y. Qu, D. Jiang, K. Li, J. Feng, S. Tian, X. Wu, Y. Wang, Y. Liu, Z. Qin, Y. Liu, J. Qin, Q. Song, X. Zhang, A. Sujie, J. Huang, T. Liu, K. Shen, J.-Y. Zhao, Y. Hou, C. Ding, Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nat. Commun. 13, 5723 (2022)PubMedPubMedCentralCrossRef
107.
J. Wang, T. Kunzke, V.M. Prade, J. Shen, A. Buck, A. Feuchtinger, I. Haffner, B. Luber, D.H.W. Liu, R. Langer, F. Lordick, N. Sun, A. Walch, Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients. Clin. Cancer Res. 28(13), 2865–2877 (2022)PubMedCrossRef
108.
Q. Xu, X. Xu, H. Tang, J. Yan, J. Li, H. Bao, X. Wu, Y. Shao, C. Luo, H. Wen, J. Jin, J. Ying, Exploring potential molecular resistance and clonal evolution in advanced her2-positive gastric cancer under trastuzumab therapy. Oncogenesis 12(1), 21 (2023)PubMedPubMedCentralCrossRef
109.
K. Chida, A. Kawazoe, T. Suzuki, M. Kawazu, T. Ueno, K. Takenouchi, Y. Nakamura, Y. Kuboki, D. Kotani, T. Kojima, H. Bando, S. Mishima, T. Kuwata, N. Sakamoto, J. Watanabe, H. Mano, M. Ikeda, K. Shitara, I. Endo, T. Nakatsura, T. Yoshino, Transcriptomic profiling of msi-h/dmmr gastrointestinal tumors to identify determinants of responsiveness to anti–pd-1 therapy. Clin. Cancer. Res. 28(10), 2110–2117 (2022)PubMedPubMedCentralCrossRef
110.
Y. Chen, Z. Sun, L. Wan, H. Chen, T. Xi, Y. Jiang: Tumor microenvironment characterization for assessment of recurrence and survival outcome in gastric cancer to predict chemotherapy and immunotherapy response. Front. Immunol. 13, 890922 (2022)PubMedPubMedCentralCrossRef
111.
B. Li, F. Zhang, Q. Niu, J. Liu, Y. Yu, P. Wang, S. Zhang, H. Zhang, Z. Wang: A molecular classification of gastric cancer associated with distinct clinical outcomes and validated by an xgboost-based prediction model. Mol. Ther. Nucleic Acids 31, 224–240 (2022)PubMedPubMedCentralCrossRef
112.
M. Aichler, B. Luber, F. Lordick, A. Walch, Proteomic and metabolic prediction of response to therapy in gastric cancer. World J. Gastroenterol. 20(38), 13648–13657 (2014)PubMedPubMedCentralCrossRef
113.
A. Smith, I. Piga, M. Galli, M. Stella, V. Denti, M. Del Puppo, F. Magni, Matrix-assisted laser desorption/ionisation mass spectrometry imaging in the study of gastric cancer: a mini review. Int. J. Mol. Sci. 18(12) (2017)
114.
S. Shrestha, S.D. Hsu, W.Y. Huang, H.Y. Huang, W. Chen, S.L. Weng, H.D. Huang, A systematic review of microrna expression profiling studies in human gastric cancer. Cancer Med. 3(4), 878–888 (2014)PubMedPubMedCentralCrossRef
115.
S.T. Kim, R. Cristescu, A.J. Bass, K.M. Kim, J.I. Odegaard, K. Kim, X.Q. Liu, X. Sher, H. Jung, M. Lee, S. Lee, S.H. Park, J.O. Park, Y.S. Park, H.Y. Lim, H. Lee, M. Choi, A. Talasaz, P.S. Kang, J. Cheng, A. Loboda, J. Lee, W.K. Kang, Comprehensive molecular characterization of clinical responses to pd-1 inhibition in metastatic gastric cancer. Nat. Med. 24(9), 1449–1458 (2018)PubMedCrossRef
116.
J. Wang, W. Liu, X. Zhang, Y. Zhang, H. Xiao, B. Luo, Lmp2a induces dna methylation and expression repression of aqp3 in ebv-associated gastric carcinoma. Virology 534, 87–95 (2019)
117.
S. Banerjee, A.D. Pal, S. Banerjee, Epstein-barr virus-encoded small non-coding rnas induce cancer cell chemoresistance and migration. Virology 443(2), 294–305 (2013)
Metadata
Title
Research advances in the molecular classification of gastric cancer
Authors
Dike Shi
Zihan Yang
Yanna Cai
Hongbo Li
Lele Lin
Dan Wu
Shengyu Zhang
Qingqu Guo
Publication date
08-05-2024
Publisher
Springer Netherlands
Published in
Cellular Oncology
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-024-00951-9
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits